Biomarker-Based Immunoassays Global Market Report 2026

Biomarker-based immunoassays are analytical methods that rely on antigen-antibody interactions to identify and measure specific biological indicators within a sample. These biomarkers may consist of proteins, hormones, or other molecular substances that reflect normal physiological functions or disease-related processes in the body. Biomarker-based immunoassays deliver highly precise and sensitive quantification, making them vital instruments in clinical diagnostics and biomedical research applications.

The primary products of biomarker-based immunoassays include consumables, instruments and analyzers, reagents and kits, and services. Consumables refer to disposable laboratory materials used during immunoassay procedures for sample preparation and testing. The different biomarker types include protein biomarkers, hormone biomarkers, cardiac biomarkers, cancer biomarkers, infectious disease biomarkers, neurological biomarkers, and autoimmune disease biomarkers and the various technologies include chemiluminescence, enzyme linked immunosorbent assay, fluorescence, multiplex, radioimmunoassay, and other technologies. The various applications involved are oncology diagnostics, cardiology diagnostics, infectious disease testing, endocrinology testing, autoimmune disease testing, neurology diagnostics, and drug discovery and development, and they are utilized by end users including clinical diagnostic laboratories, pharmaceutical research and development, contract research organizations, hospitals and clinics, and academic research institutes.

Tariffs are affecting the biomarker-based immunoassays market by raising the cost of imported reagents, diagnostic kits, instruments, and specialized analytical equipment used in laboratory testing. This is impacting clinical diagnostic laboratories, hospitals, and research institutes, particularly in regions dependent on imports such as Asia-Pacific and Latin America. High-cost segments such as automated immunoassay analyzers and multiplex assay platforms are the most affected due to reliance on global supply chains. However, tariffs are also encouraging local manufacturing of diagnostic kits, regional reagent production, and investment in domestic biotechnology infrastructure, supporting long-term market self-reliance and innovation.

The biomarker-based immunoassays market research report is one of a series of new reports from The Business Research Company that provides biomarker-based immunoassays market statistics, including biomarker-based immunoassays industry global market size, regional shares, competitors with a biomarker-based immunoassays market share, detailed biomarker-based immunoassays market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker-based immunoassays industry. This biomarker-based immunoassays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biomarker-based immunoassays market size has grown rapidly in recent years. It will grow from $6.6 billion in 2025 to $7.37 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases driving demand for early diagnostic testing, growing use of enzyme linked immunosorbent assay in clinical laboratories, expansion of hospital diagnostic infrastructure and laboratory networks, rising adoption of antibody based detection techniques in research applications, development of standardized biomarker identification methods in biomedical research.

The biomarker-based immunoassays market size is expected to see rapid growth in the next few years. It will grow to $11.55 billion by 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to rising demand for personalized medicine and precision diagnostics, increasing integration of ai and machine learning in biomarker analysis, growing adoption of multiplex and high throughput immunoassay technologies, expansion of point of care diagnostic testing in remote healthcare settings, increasing investment in pharmaceutical research and drug discovery applications. Major trends in the forecast period include ai driven biomarker interpretation and predictive disease modeling for enhanced diagnostic accuracy, multiplex immunoassay platforms enabling simultaneous detection of multiple biomarkers, cloud integrated immunoassay systems for centralized diagnostic data management, lab automation and robotic sample processing for high throughput immunoassay testing, next generation point of care immunoassay devices for rapid clinical diagnostics.

The increasing incidence of oncology cases is expected to propel the growth of the biomarker-based immunoassays market going forward. Oncology cases refer to the occurrence of cancers caused by abnormal and uncontrolled cell growth that can spread to different parts of the body. The rising incidence of oncology cases is driven primarily by aging populations, as the risk of developing cancer increases significantly with age and longer life expectancy leads to a higher number of diagnosed cases. Biomarker-based immunoassays support the management of oncology cases by enabling early detection, precise monitoring of disease progression, and guiding personalized treatment decisions through accurate identification of cancer-specific biomarkers. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are projected in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing incidence of oncology cases is contributing to and propelling the growth of the biomarker-based immunoassays market.

Leading companies operating in the biomarker-based immunoassays market are focusing on developing innovative solutions such as ultrasensitive immunoassay platforms to enable early and accurate detection of low-abundance biomarkers. Ultrasensitive immunoassay platforms are advanced diagnostic systems designed to detect extremely low concentrations of biomarkers with high precision and specificity, helping enable earlier disease detection, improved diagnostic accuracy, and better monitoring of disease progression compared to conventional assays. For example, in July 2025, Spear Bio Inc., a US-based biotechnology company, launched SPEAR UltraDetect, a next-generation ultrasensitive immunoassay solution designed to enhance biomarker detection in neurodegenerative disease research. The platform utilizes proprietary homogeneous assay technology that eliminates the need for wash steps, unlike traditional heterogeneous immunoassays, enabling faster and more streamlined workflows. It is capable of detecting protein biomarkers at attomolar concentrations using as little as 1 µL of sample, significantly improving sensitivity and efficiency. The solution includes assays targeting key neurological biomarkers such as pTau217, pTau231, GFAP, and NfL, supporting early and accurate disease analysis.

In July 2025, Alden Scientific Inc., a US-based healthcare technology company, acquired Oncimmune Germany GmbH for an undisclosed amount. With this acquisition, Alden Scientific Inc. aims to improve its multi-omic and precision medicine capabilities by integrating advanced immunodiagnostics and biomarker discovery technologies, thereby strengthening its ability to study immune-mediated diseases and expand its data-driven health platform. Oncimmune Germany GmbH is a Germany-based healthcare technology company specializing in immunodiagnostics and autoantibody biomarker discovery services through its proprietary platforms.

Major companies operating in the biomarker-based immunoassays market are Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Eurofins Scientific SE, Bio-Rad Laboratories Inc., QIAGEN N. V., Tecan Trading AG, Autobio Diagnostics Co. Ltd., Promega Corporation, Sekisui Diagnostics LLC, Boditech Med Inc., Dynex Technologies Inc., NanoEntek Inc., J. Mitra & Co. Pvt. Ltd., ALPCO Diagnostics LLC, Micropoint Bioscience Inc., Coris BioConcept, MiCo BioMed Co. Ltd., Abionic SA, ANP Technologies Inc., Axela Inc., Epitope Diagnostics Inc., MedMira Inc., Nanomix Inc.

North America was the largest region in the biomarker-based immunoassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker-based immunoassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biomarker-based immunoassays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biomarker-based immunoassays market consists of sales of rapid test kits, chemiluminescent immunoassay kits, multiplex assay kits, antibodies, reagents, lateral flow readers, and flow cytometers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biomarker-Based Immunoassays Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses biomarker-based immunoassays market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biomarker-based immunoassays ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biomarker-based immunoassays market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Consumables; Instruments And Analyzers; Reagents And Kits; Services
• 2) By Biomarker Type: Protein Biomarkers; Hormone Biomarkers; Cardiac Biomarkers; Cancer Biomarkers; Infectious Disease Biomarkers; Neurological Biomarkers; Autoimmune Disease Biomarkers
• 3) By Technology: Chemiluminescence; Enzyme Linked Immunosorbent Assay; Fluorescence; Multiplex; Radioimmunoassay; Other Technologies
• 4) By Application: Oncology Diagnostics; Cardiology Diagnostics; Infectious Disease Testing; Endocrinology Testing; Autoimmune Disease Testing; Neurology Diagnostics; Drug Discovery And Development
• 5) By End-User: Clinical Diagnostic Laboratories; Pharmaceutical Research And Development; Contract Research Organizations; Hospitals And Clinics; Academic Research Institutes
• Subsegments:
• 1) By Consumables: Pipette Tips; Microplates; Sample Containers; Microcentrifuge Tubes; Reagent Reservoirs; Disposable Pipettes
• 2) By Instruments And Analyzers: Enzyme Linked Immunosorbent Assay Analyzers; Chemiluminescence Immunoassay Analyzers; Fluorescence Immunoassay Systems; Multiplex Assay Platforms; Radioimmunoassay Instruments; Automated Immunoassay Analyzers
• 3) By Reagents And Kits: Enzyme Linked Immunosorbent Assay Kits; Chemiluminescence Immunoassay Reagents; Fluorescence Immunoassay Reagents; Multiplex Assay Kits; Radioimmunoassay Kits; Controls And Standards
• 4) By Services: Assay Development Services; Sample Testing Services; Data Analysis Services; Technical Support Services; Clinical Trial Support Services; Training And Consultation Services
• Companies Mentioned: Thermo Fisher Scientific Inc.; Abbott Laboratories; Merck KGaA; Eurofins Scientific SE; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Tecan Trading AG; Autobio Diagnostics Co. Ltd.; Promega Corporation; Sekisui Diagnostics LLC; Boditech Med Inc.; Dynex Technologies Inc.; NanoEntek Inc.; J. Mitra & Co. Pvt. Ltd.; ALPCO Diagnostics LLC; Micropoint Bioscience Inc.; Coris BioConcept; MiCo BioMed Co. Ltd.; Abionic SA; ANP Technologies Inc.; Axela Inc.; Epitope Diagnostics Inc.; MedMira Inc.; Nanomix Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.